The findings, which have implications for cancer and other diseases, resulted from capturing the first snapshot of a mechanical signaling complex in action.

The study overturns decades-long assumptions about why HBV fails to infect mouse liver cells, pointing towards a new disease model.

Shixin Liu is pioneering new ways of studying the tiny proteins that copy and transcribe genetic code.

The findings may lead to new therapeutic interventions for certain types of neurodegeneration and cancers.

By editing blood stem cells, researchers show that the immune system itself can be transformed into a durable, boostable source of therapeutic proteins—opening the door to novel treatments

Researchers devised a platform for mapping the regulatory nodes where genetic variations converge to drive changes in cell behavior.

Three years in, the Stavros Niarchos Foundation Institute for Global Infectious Disease Research has matured into a working pipeline connecting basic science and emerging therapies.

Researchers created the first mouse model in which chronic viral infection progresses to liver cancer, closely mirroring what happens in people with hepatitis C.

The Rockefeller teams will map immune cell interactions, engineer cells as drug delivery systems, and activate immune responses in hard-to-treat cancers.

Theodora Hatziioannou used her expertise on HIV-1 to gain insights into SARS-Co-V-2, and vice versa. The potential applications of her insights could be much broader.
View
View